IAI Accepts, published online ahead of print on 26 October 2009

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Neal, L. M. Articles by Mantis, N. J. PubMed PubMed Citation Articles by Neal, L. M. Articles by Mantis, N. J.

 Previous Article  |  Next Article 

Infect. Immun. doi:10.1128/IAI.00796-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

A Monoclonal IgG Antibody Directed against an Immunodominant Linear Epitope on the Ricin A Chain Confers Systemic and Mucosal Immunity to Ricin

Lori M. Neal, Joanne O'Hara, Robert N. Brey III, and Nicholas J. Mantis^*

Division of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY 12208; Department of Biomedical Sciences, University at Albany School of Public Health, Albany, NY 12201; Soligenix, Ewing, NJ 08628

^* To whom correspondence should be addressed. Email: nmantis{at}wadsworth.org.

Due to the potential use of ricin and other fast-acting toxins as agents of bioterrorism, there is an urgent need for the development of safe and effective anti-toxin vaccines. A candidate ricin subunit vaccine (RiVax^TM) consisting of a recombinant attenuated enzymatic A chain (RTA) has been shown to elicit protective anti-toxin antibodies in mice and rabbits, and is currently being tested in Phase I human clinical trials. However, evaluation of the efficacy of this vaccine in humans is difficult for a number of reasons, including the fact that the key neutralizing B cell epitopes on RTA have not been fully defined. Castelletti and colleagues (Clin. Exp. Immunol. 136: 365) recently identified a linear epitope on RTA spanning residues L161 to I175, as being a primary target of serum antibodies derived from humans who had been treated with ricin immunotoxin. While affinity-purified polyclonal IgG antibodies against this region of RTA were capable of neutralizing ricin in vitro, their capacity to confer protection against ricin challenge in vivo was not determined. In this report, we describe the production and characterization of GD12, a murine monoclonal IgG₁ antibody (MAb) specifically directed against residues 163 -174 (TLARSFIICIQM) of RTA. GD12 bound ricin holotoxin with high affinity (K_D 2.9 x 10^-9 M) and neutralized it with an IC₅₀ of 0.25 μg/ml, as determined by a Vero cell-based cytotoxicity assay. Passive administration of GD12 was sufficient to protect BALB/c mice against intraperitoneal and intragastric ricin challenges. These data are important in terms of vaccine development as they firmly establish that pre-existing serum antibodies directed against residues 161-175 on RTA are sufficient to confer both systemic and mucosal immunity to ricin. The potential of GD12 to serve as a therapeutic following ricin challenge was not explored in this study.